Compare EDBL & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDBL | BDRX |
|---|---|---|
| Founded | 2020 | 2000 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 4.0M |
| IPO Year | 2022 | N/A |
| Metric | EDBL | BDRX |
|---|---|---|
| Price | $0.78 | $2.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 190.2K | ★ 2.8M |
| Earning Date | 11-14-2025 | 09-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,553,000.00 | N/A |
| Revenue This Year | $29.56 | N/A |
| Revenue Next Year | $20.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $2.22 |
| 52 Week High | $10.60 | $92.00 |
| Indicator | EDBL | BDRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.24 | 38.79 |
| Support Level | $0.48 | $2.22 |
| Resistance Level | $1.04 | $2.63 |
| Average True Range (ATR) | 0.14 | 0.40 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 29.93 | 3.77 |
Edible Garden AG Inc is a next-generation controlled environment agriculture farming company. It uses traditional agricultural growing techniques together with technology to grow fresh, organic food, sustainably and safely while improving traceability. The company uses the controlled environment of traditional greenhouse structures, such as glass greenhouses together with hydroponic and vertical greenhouses to sustainably grow organic herbs and lettuces.
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.